Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies.
In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.
18-90 years of age
Provision of a written informed consent
Affiliation with a social security scheme or beneficiary of such a scheme
Diagnosed by a clinically certified laboratory with a disease- causing mutation in a known ALS gene by predictive genetic testing
Inability to express consent to the study
Persons subject to a judicial safeguard measure, under guardianship or curatorship.
Linguistic incapacity or psychic refusal to read the information.
Pregnant women
Institut National de la Santé Et de la Recherche Médicale, France
Lead sponsor
Technical University of Munich
Collaborator